Status:

COMPLETED

Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid

Lead Sponsor:

Assistance Publique Hopitaux De Marseille

Conditions:

Hutchinson-Gilford Progeria Syndrome

Eligibility:

All Genders

3+ years

Phase:

PHASE2

Brief Summary

We suggest treating the Hutchinson-Gilford Progeria Syndrome by two molecules (zoledronic acid and pravastatin).The therapeutic approach which we propose has for objectives to reduce, to prevent or to...

Eligibility Criteria

Inclusion

  • Molecularly characterised patients with a known mutation of their LMNA gene leading to the production of a farnesylated prelamin A, whether truncated or not
  • Patients must be able to travel and consult in Marseille, France for necessary explorations planned at the inclusion step, then following the protocol flow
  • chart for zoledronic acid injections and follow-up visits
  • Patient older than 3 years
  • Patients affiliated or beneficiary of a legal medical insurance
  • Adult patients certifying they have been properly informed about the protocol, and they signed a written consent form. Children and/or disabled patients whose parents/legal tutor have been informed and have signed a written consent form

Exclusion

  • Known hypersensitivity to pravastatin or zoledronic acid
  • Seric transaminase levels higher than 3 times of normal value
  • CPK level higher than 5 times of normal value
  • Creatininemia higher than 0.5mg/dl or 44mM, or creatinin clearance lower than 70ml/min/1.73m3
  • Presence of dental troubles, or recent dental trouble
  • Maxillary osteonecrosis or bone nakedness antecedent
  • Congenital galacosemia, glucose or galactose maladsorption syndrome, lactase deficiency
  • Every other pathology thought to be incompatible with proposed treatment by the investigator
  • Under treatment that can interfere with pravastatin and/or zoledronate metabolisms

Key Trial Info

Start Date :

October 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2013

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00731016

Start Date

October 1 2008

End Date

July 1 2013

Last Update

July 8 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Laboratoire de Génétique Moléculaire - Hopital de la Timone

Marseille, France, 13385